RETRACTED: Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression

Salimifard, Sevda; Kiani, Fariba Karoon; Eshaghi, Farzaneh Sadat; Izadi, Sepideh; Shahdadnejad, Kolsoom; Masjedi, Ali; Heydari, Morteza; Ahmadi, Armin; Hojjat‐Farsangi, Mohammad; Hassannia, Hadi; Mohammadi, Hamed; Boroumand-Noughabi, Samaneh; Keramati, Mohammad Reza; Jadidi‐Niaragh, Farhad

doi:10.1016/j.lfs.2020.118423

Cited by 26 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results indicated that this nanoparticle size was 100 nm and this combination may enhance apoptosis while decreasing cell migration, proliferation, and colony formation in the cell lines 4T1 and CT26. When these nanoparticles were delivered to the experimental animals, they likewise exhibited an increase in survival time [74]. In addition, carboxylate graphene oxide and trimethyl chitosan coupled with hyaluronic acid-based ligands were used to produce CHA-Np to entrap HIF-1α siRNA and dinaciclib (95 nm).…”

Section: Colon Cancermentioning

confidence: 99%

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

Cancer is the most common cause of death worldwide; therefore, there is a need to discover novel treatment modalities to combat it. One of the cancer treatments is nanoparticle technology. Currently, nanoparticles have been modified to have desirable pharmacological effects by using chemical ligands that bind with their specific receptors on the surface of malignant cells. Chemical grafting of chitosan nanoparticles with hyaluronic acid as a targeted ligand can become an attractive alternative for active targeting. Hence, these nanoparticles can control drug release with pH- responsive stimuli, and high selectivity of hyaluronic acid to CD44 receptors makes these nanoparticles accumulate more inside cells that overexpress these receptors (cancer cells). In this context, we discuss the benefits and recent findings of developing and utilizing chitosan–hyaluronic acid nanoparticles against distinct forms of cancer malignancy. From here we know that chitosan–hyaluronic acid nanoparticles (CHA-Np) can produce a nanoparticle system with good characteristics, effectiveness, and a good active targeting on various types of cancer cells. Therefore, this system is a good candidate for targeted drug delivery for cancer therapy, anticipating that CHA-Np could be further developed for various cancer therapy applications.

show abstract

Section: Colon Cancermentioning

confidence: 99%

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Similarly, the hyaluronate-PEG-chitosanlactate (H-PCL) NPs were designed for the concurrent delivery of BV6, a apoptotic inhibitor and IL-6 specific siRNA and evaluated the anti-tumor properties in cell line and animals systems. The rdata revealed that H-PCL NPs increased apoptosis and concomitantly reduced the tumor forming events in 4T1 and CT26 cells such as proliferation, migration, colony formation, and angiogenesis as well as suppressed cancer formation in tumor-bearing mice [172].…”

Section: High Expression Of Apoptosis Inhibitors In Tumor Cells Incre...mentioning

confidence: 97%

Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics

Prateeksha

Sharma

Liu

et al. 2022

Seminars in Cancer Biology

View full text Add to dashboard Cite

“…The results showed that such nanoparticles could reduce both in vitro and in vivo tumour growth and angiogenesis by decreasing the expression of related genes, including TGF, VEGF, and FGF, in colorectal cancer ( 148 ). Some similar studies reported that chitosan-based nanoparticles loaded with IL-6-specific siRNA and HIF-1α-specific siRNA could inhibit colorectal cancer progression and angiogenesis ( 149 , 150 ). Epirubicin (EPI), as an anthracycline derivative, is a first-line chemotherapy drug against various digestive tumours ( 151 ).…”

Section: Anti-angiogenic Nanoparticles In Digestive Tumoursmentioning

confidence: 99%

Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies

et al. 2022

View full text Add to dashboard Cite

Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that abnormal angiogenesis plays an important role in the growth, progression, and metastasis of digestive tumours. Therefore, anti-angiogenic therapy is considered a promising target for improving therapeutic efficacy. Traditional strategies such as bevacizumab and regorafenib can target and block the activity of proangiogenic factors to treat digestive tumours. However, due to resistance and some limitations, such as poor pharmacokinetics, their efficacy is not always satisfactory. In recent years, nanotechnology-based anti-angiogenic therapies have emerged as a new way to treat digestive tumours. Compared with commonly used drugs, nanoparticles show great potential in tumour targeted delivery, controlled drug release, prolonged cycle time, and increased drug bioavailability. Therefore, anti-angiogenic nanoparticles may be an effective complementary therapy to treat digestive tumours. In this review, we outline the different mechanisms of angiogenesis, the effects of nanoparticles on angiogenesis, and their biomedical applications in various kinds of digestive tumours. In addition, the opportunities and challenges are briefly discussed.

show abstract

RETRACTED: Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression

Cited by 26 publications

References 39 publications

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics

Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies

Contact Info

Product

Resources

About